<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874094</url>
  </required_header>
  <id_info>
    <org_study_id>08.01</org_study_id>
    <nct_id>NCT00874094</nct_id>
  </id_info>
  <brief_title>Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds</brief_title>
  <official_title>Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The New York Eye &amp; Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The New York Eye &amp; Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelets are a component of blood, which contain factors which can enhance wound healing.
      This study proposes to evaluate the clinical response of laugh lines treated with a
      concentrated preparation of the subject's own platelets injected into or under the skin by
      taking serial photographs of the subject's face over a 12 week period. Also, the same
      preparation will be injected into or under the skin of the arm near the elbows, and serial
      biopsies will be taken over a 12 week period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Wrinkle Assessment Score, Between Pre-treatment and 12 Weeks Post-treatment.</measure>
    <time_frame>Difference in Measurements taken Pre-treatment and 12 weeks after treatment.</time_frame>
    <description>Difference in wrinkle assessment score, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale)between pre-treatment and 12 weeks post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Wrinkle Assessment Scores Between Pre-treatment and 1 Week</measure>
    <time_frame>pre-treatment to 1 week after treatment</time_frame>
    <description>Difference in Wrinkle Assessment Scores, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale), between Pre-treatment and 1 week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Wrinkle Assessment Score Between Pretreatment and 2 Weeks</measure>
    <time_frame>Pre-treatment to 2 weeks after treatment</time_frame>
    <description>Difference in Wrinkle Assessment Scores, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale), between Pre-treatment and 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Wrinkle Assessment Score Between Pretreatment and 6 Weeks</measure>
    <time_frame>Pre-treatment to 6 weeks after treatment</time_frame>
    <description>Difference in Wrinkle Assessment Scores, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale), between Pre-treatment and 6 Weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>platelet rich fibrin matrix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Both nasolabial folds treated with 0-2 cc of autologous platelet rich fibrin matrix,sufficient to efface nasolabial fold</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet rich fibrin matrix</intervention_name>
    <description>0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.</description>
    <arm_group_label>platelet rich fibrin matrix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adults

          -  aged 25- 75 years

          -  with moderate to severe nasolabial folds

        Exclusion Criteria:

          -  pregnant

          -  allergy to local anesthetics

          -  history of bleeding disorder

          -  active infection at the treatment site

          -  injectable filler in the nasolabial folds within past year
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony P Sclafani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The New York Eye &amp; Ear Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The New York Eye &amp; Ear Infirmary- Otolaryngology Faculty practice satellite</name>
      <address>
        <city>Chappaqua</city>
        <state>New York</state>
        <zip>10514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sclafani AP. Platelet-rich fibrin matrix for improvement of deep nasolabial folds. J Cosmet Dermatol. 2010 Mar;9(1):66-71. doi: 10.1111/j.1473-2165.2010.00486.x.</citation>
    <PMID>20367676</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2009</study_first_submitted>
  <study_first_submitted_qc>April 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <results_first_submitted>July 18, 2011</results_first_submitted>
  <results_first_submitted_qc>July 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2013</results_first_posted>
  <last_update_submitted>July 10, 2013</last_update_submitted>
  <last_update_submitted_qc>July 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nasolabial folds</keyword>
  <keyword>platelet rich plasma</keyword>
  <keyword>fibrin matrix</keyword>
  <keyword>facial rhytids</keyword>
  <keyword>dermal filler</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with moderate to severe nasolabial folds were included.</recruitment_details>
      <pre_assignment_details>Any patient who refused to attend all scheduled follow up visits were to be excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment With Platelet Rich Fibrin Matrix</title>
          <description>Both nasolabial folds treated with platelet rich fibrin matrix</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment With Platelet Rich Fibrin Matrix</title>
          <description>Both nasolabial folds treated with platelet rich fibrin matrix</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.27" spread="12.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Wrinkle Assessment Score, Between Pre-treatment and 12 Weeks Post-treatment.</title>
        <description>Difference in wrinkle assessment score, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale)between pre-treatment and 12 weeks post-treatment.</description>
        <time_frame>Difference in Measurements taken Pre-treatment and 12 weeks after treatment.</time_frame>
        <population>Number of participants were calculated based on need to achieve 1 unit improvement of Wrinkle Assessment score over baseline (pre-treatment) to be clinically relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Platelet Rich Fibrin Matrix</title>
            <description>Both nasolabial folds treated with platelet rich fibrin matrix</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Wrinkle Assessment Score, Between Pre-treatment and 12 Weeks Post-treatment.</title>
          <description>Difference in wrinkle assessment score, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale)between pre-treatment and 12 weeks post-treatment.</description>
          <population>Number of participants were calculated based on need to achieve 1 unit improvement of Wrinkle Assessment score over baseline (pre-treatment) to be clinically relevant.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Wrinkle Assessment Scores Between Pre-treatment and 1 Week</title>
        <description>Difference in Wrinkle Assessment Scores, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale), between Pre-treatment and 1 week</description>
        <time_frame>pre-treatment to 1 week after treatment</time_frame>
        <population>The number of participants required to demonstrate a 1 point difference between pre and post treatment values</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Platelet Rich Fibrin Matrix</title>
            <description>Both nasolabial folds treated with platelet rich fibrin matrix</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Wrinkle Assessment Scores Between Pre-treatment and 1 Week</title>
          <description>Difference in Wrinkle Assessment Scores, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale), between Pre-treatment and 1 week</description>
          <population>The number of participants required to demonstrate a 1 point difference between pre and post treatment values</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".65" spread=".68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Wrinkle Assessment Score Between Pretreatment and 2 Weeks</title>
        <description>Difference in Wrinkle Assessment Scores, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale), between Pre-treatment and 2 weeks</description>
        <time_frame>Pre-treatment to 2 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Platelet Rich Fibrin Matrix</title>
            <description>Both nasolabial folds treated with platelet rich fibrin matrix</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Wrinkle Assessment Score Between Pretreatment and 2 Weeks</title>
          <description>Difference in Wrinkle Assessment Scores, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale), between Pre-treatment and 2 weeks</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".97" spread=".75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Wrinkle Assessment Score Between Pretreatment and 6 Weeks</title>
        <description>Difference in Wrinkle Assessment Scores, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale), between Pre-treatment and 6 Weeks</description>
        <time_frame>Pre-treatment to 6 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Platelet Rich Fibrin Matrix</title>
            <description>Both nasolabial folds treated with platelet rich fibrin matrix</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Wrinkle Assessment Score Between Pretreatment and 6 Weeks</title>
          <description>Difference in Wrinkle Assessment Scores, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale), between Pre-treatment and 6 Weeks</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread=".59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment With Platelet Rich Fibrin Matrix</title>
          <description>Both nasolabial folds treated with platelet rich fibrin matrix</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anthony P Sclafani, MD</name_or_title>
      <organization>NY Eye &amp; Ear Infirmary</organization>
      <phone>212-979-4200</phone>
      <email>asclafani@nyee.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

